What are late breaking abstracts?
Abstracts that describe important current research advances that have not been submitted previously. Please note: Late breaking abstracts are not a second chance to submit a study for the second time in hope to be selected for an oral presentation.
Individuals listed as first authors of standard abstracts are not prohibited from submitting late-breaking abstracts, provided that the late breaking abstract describes a study different from the previously submitted study. Individuals submitting a late breaking abstract must indicate authors and coauthors that have already submitted a standard abstract.
Selection of abstracts will be based on scientific quality and novelty of research either in basic or clinical science. In order to be considered for presentation at the World Allergy Congress 2005, late-breaking abstracts must be submitted via this website. The submission deadline for late breaking abstracts is April 11th.For more information, contact Congrex at: email@example.com
Only abstracts not published elsewhere or submitted for presentation at another national and/or international meeting will be considered for presentation.
ABSTRACT SUBMISSION DEADLINE: 11 APRIL
Registration and payment
Carefully read the guidelines in this announcement before submitting
your abstract. Acknowledgement of receipt of your submission will be returned
to your e-mail address immediately upon submission. If you do not receive
the e-mail, your submission was not completed and your abstract needs
In order to make the abstract as informative as possible, please include a brief statement of the purpose of the study, the method used, the result observed, and the conclusions based upon the results. It is inadequate to state "The results will be discussed" or "The data will be presented". You may subtitle the paragraphs in bold format in the following order: Background, Method, Results, and Conclusion.
The abstract title and body text should only include pharmacopeia names printed in lower case. Trade names are not allowed. Non-proprietary (generic) names of drugs, written in lower case, are required at the first place a drug is mentioned. References, credits or the authors’ academic degrees or grant support are not to be included in the abstract. Standard abbreviations may be employed in the text. Place special or unusual abbreviations in parentheses after the full wording at the first time it appears in the body of the text.
Accepted abstracts selected by expert reviewers will be presented in oral and poster sessions. Poster presenters will be asked to be present by their poster during poster session. Authors should indicate in the space provided the preferred method of presentation.
It is the author's responsibility to submit a correct abstract. Any errors in spelling, grammar or scientific fact will be reproduced as typed by the author. Please note that each year a number of abstracts are rejected because they contain no data or the English is unacceptable. Changes to abstracts can only be accepted until the submission deadline by using the Personal Page. You can access your Personal Page by using your password included in the e-mail received upon submission.
Notification of acceptance
Publication of abstracts